Monitor for any regulatory milestone updates (NDA submission timing, Breakthrough Therapy Designation) as the primary catalyst; the PeDRA poster data is incremental and unlikely to move the stock materially without a hard regulatory catalyst.
Price Chart
Executive Summary
Palvella Therapeutics announced poster presentations at the PeDRA Annual Conference featuring new pediatric analyses from its Phase 3 SELVA and Phase 2 TOIVA studies of QTORIN rapamycin for microcystic lymphatic malformations and cutaneous venous malformations. The company reported Q2 2026 EPS of -$1.52, a 12.8% beat vs consensus of -$1.74, though the stock remains a pre-revenue clinical-stage biotech with no approved products.
Key Financial Metrics
Key Facts
- Palvella presenting two posters at PeDRA Annual Conference (Oct 15-17, 2026) with new pediatric analyses from Phase 3 SELVA and Phase 2 TOIVA studies
- QTORIN rapamycin targets microcystic lymphatic malformations and cutaneous venous malformations, both with no FDA-approved therapies
- Q2 2026 EPS of -$1.52 beat consensus of -$1.74 by 12.8%
- Company remains pre-revenue with no approved products; revenue consensus was $0
Financial Impact
EPS beat of 12.8% vs consensus; no revenue reported as company is pre-commercial
Risk Factors
- No FDA-approved products; clinical-stage risk with no guaranteed regulatory path
- Cash runway and need for future capital raises given pre-revenue status
- EPS beat is on a small absolute base (-$1.52 vs -$1.74) and does not change fundamental business trajectory
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3381533 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | Insider Cluster | $126.23 | awaiting T+60 | — | $132.91 (+5.29%) |
Oct 15, 2026 12d ago | Press Release | $127.34 | awaiting T+60 | — | $132.91 (+4.37%) |
Oct 13, 2026 14d ago | 144 | $122.58 | awaiting T+60 | — | $132.91 (+8.43%) |
Sep 18, 2026 5w ago | Insider Cluster | $153.41 | awaiting T+60 | — | $132.91 (+13.36%) |
Sep 2, 2026 7w ago | 144 | $155.47 | awaiting T+60 | — | $132.91 (−14.51%) |
Aug 9, 2026 11w ago | Institutional Cluster | $152.22 | awaiting T+60 | — | $132.91 (−12.69%) |
Aug 4, 2026 12w ago | 8-K | $151.99 | awaiting T+60 | — | $132.91 (−12.55%) |
Jul 30, 2026 12w ago | Press Release | $150.19 $125.10 | ▼ −16.71% | ▼ −19.17% | $132.91 (−11.51%) |
Jul 28, 2026 13w ago | Press Release | $142.84 $126.58 | ▼ −11.38% | ▼ −15.73% | $132.91 (−6.95%) |
Jun 30, 2026 17w ago | 8-K | $152.82 $149.56 | ▼ −2.13% | ▼ −5.70% | $132.91 (−13.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers